Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy

The primary objective of this study is to assess the major pathological response (MPR) rate and pathologic complete response (pCR) rate in stage IB-IIIA non-small cell lung cancer (NSCLC) treated with a low dose of neoadjuvant immunotherapy combined with platinum doublet.

Trial Details

NCT ID
NCT06667154
Phase
PHASE2
Sponsor
Aline Fusco Fares, MD
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Low-dose nivolumab combined with platinum-based doublet chemotherapy
Locations (sample)
  • São José do Rio Preto, São Paulo, Brazil|-20.81972,-49.37944

Key Eligibility Criteria

  • Able to provide a signed Informed Consent Form (ICF), indicating agreement to comply with the requirements and restrictions in the ICF and protocol.
  • Male or female, aged 18 years or older.
  • Diagnosed with non-small cell lung cancer (NSCLC) with clinical staging IB, II, or IIIA.
  • Receiving treatment at Hospital de Base.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →